{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:44:37Z","timestamp":1770079477648,"version":"3.49.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1097\/fpc.0000000000000233","type":"journal-article","created":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T11:07:59Z","timestamp":1466766479000},"page":"423-427","source":"Crossref","is-referenced-by-count":25,"title":["HLA-Cw6 allele, NFkB1 and NFkBIA polymorphisms play no role in predicting response to etanercept in psoriatic patients"],"prefix":"10.1097","volume":"26","author":[{"given":"Giacomo","family":"Caldarola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Sgambato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Fanali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaia","family":"Moretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Lucchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210213","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2217\/pgs.11.114","article-title":"Genetic and genomic predictors of anti-TNF-alpha response","volume":"12","author":"Prajapati","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R2-3-20210213","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/dth.12251","article-title":"New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors","volume":"28","author":"Gaspari","year":"2015","journal-title":"Dermatol Ther"},{"key":"R3-3-20210213","first-page":"613086","article-title":"Genetics of psoriasis and pharmacogenetics of biological drugs","volume":"2013","author":"Prieto-P\u00e9rez","year":"2013","journal-title":"Autoimmune Dis"},{"key":"R4-3-20210213","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2217\/pgs.15.90","article-title":"Association between TNF-\u03b1 (\u2212308 A\/G, \u2212238 A\/G, \u2212857 C\/T) polymorphisms and responsiveness to TNF-\u03b1 blockers in spondyloarthropathy, psoriasis and Crohn\u2019s disease: a meta-analysis","volume":"16","author":"Song","year":"2015","journal-title":"Pharmacogenomics"},{"key":"R5-3-20210213","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/jdv.13024","article-title":"TNF-alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients","volume":"29","author":"De Simone","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R6-3-20210213","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/ard.2009.117309","article-title":"Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways","volume":"69","author":"Potter","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R7-3-20210213","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0092-8674(00)81318-5","article-title":"NF-kappa B: ten years after","volume":"87","author":"Baeuerle","year":"1996","journal-title":"Cell"},{"key":"R8-3-20210213","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0968-0004(92)90321-Y","article-title":"NF-kappa B and related proteins: Rel\/dorsal homologies meet ankyrin-like repeats","volume":"17","author":"Blank","year":"1992","journal-title":"Trends Biochem Sci"},{"key":"R9-3-20210213","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.cell.2006.12.005","article-title":"SnapShot: NF-kappaB signalling pathways","volume":"127","author":"Hayden","year":"2006","journal-title":"Cell"},{"key":"R10-3-20210213","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/bjd.12331","article-title":"Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B\/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12\/23 blocker ustekinumab","volume":"169","author":"Talamonti","year":"2013","journal-title":"Br J Dermatol"},{"key":"R11-3-20210213","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/bjd.13056","article-title":"Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12\/23 blocker, in Chinese patients with psoriasis: a retrospective analysis","volume":"171","author":"Chiu","year":"2014","journal-title":"Br J Dermatol"},{"key":"R12-3-20210213","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jaad.2015.08.055","article-title":"HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: outcome and long-term follow-up","volume":"74","author":"Talamonti","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R13-3-20210213","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat Commun"},{"key":"R14-3-20210213","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/FPC.0000000000000136","article-title":"The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients","volume":"25","author":"Batalla","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"R15-3-20210213","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.12425","article-title":"The relationship between tumour necrosis factor (TNF)-\u03b1 promoter and IL12B\/IL-23R genes polymorphisms and the efficacy of anti-TNF-\u03b1 therapy in psoriasis: a case-control study","volume":"169","author":"Gallo","year":"2013","journal-title":"Br J Dermatol"},{"key":"R16-3-20210213","first-page":"125","article-title":"New developments in the pharmacogenetics of psoriasis: HLA-Cw6 as a marker for the treatment of psoriasis with biological therapies","volume":"1","author":"Costanzo","year":"2010","journal-title":"Adv Psor Inflam Skin Dis"},{"key":"R17-3-20210213","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1365-2133.2011.10213.x","article-title":"Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris","volume":"164","author":"Gniadecki","year":"2011","journal-title":"Br J Dermatol"},{"key":"R18-3-20210213","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1468-3083.2010.03944.x","article-title":"Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE","volume":"25","author":"Ortonne","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R19-3-20210213","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis \u2013 oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"R20-3-20210213","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s100380050125","article-title":"Isolation and radiation hybrid mapping of a highly polymorphic CA repeat sequence at the human nuclear factor kappa-beta subunit 1 (NFKB1) locus","volume":"44","author":"Ota","year":"1999","journal-title":"J Hum Genet"},{"key":"R21-3-20210213","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1744-313X.2005.00546.x","article-title":"A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis","volume":"32","author":"Borm","year":"2005","journal-title":"Int J Immunogenet"},{"key":"R22-3-20210213","doi-asserted-by":"crossref","first-page":"e21726","DOI":"10.1371\/journal.pone.0021726","article-title":"NF\u03baB1 and NF\u03baBIA polymorphisms are associated with increased risk for sporadic colorectal cancer in a southern Chinese population","volume":"6","author":"Song","year":"2011","journal-title":"PLoS One"},{"key":"R23-3-20210213","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00403-008-0843-4","article-title":"Association study of NFKB1 and SUMO4 polymorphisms in Chinese patients with psoriasis vulgaris","volume":"300","author":"Li","year":"2008","journal-title":"Arch Dermatol Res"},{"key":"R24-3-20210213","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/BF00201573","article-title":"Polymorphisms in the 39 untranslated region of the I kappa B\/MAD-3 (NFKBI) gene located on chromosome 14","volume":"93","author":"Glavac","year":"1994","journal-title":"Hum Genet"},{"key":"R25-3-20210213","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00384-003-0531-y","article-title":"A polymorphism of the NFKBIA gene is associated with Crohn\u2019s disease patients lacking a predisposing allele of the CARD15 gene","volume":"19","author":"Klein","year":"2004","journal-title":"Int J Colorectal Dis"},{"key":"R26-3-20210213","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/humu.9146","article-title":"Identification of variants in NFKBIA and association analysis with hepatocellular carcinoma risk among chronic HBV patients","volume":"21","author":"Kim","year":"2003","journal-title":"Hum Mutat"},{"key":"R27-3-20210213","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1038\/ncomms7793","article-title":"Whole-exome SNP array identifies 15 new susceptibility loci for psoriasis","volume":"6","author":"Zuo","year":"2015","journal-title":"Nat Commun"},{"key":"R28-3-20210213","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1523-1747.1999.00724.x","article-title":"HLA-Cw6 and the genetic predisposition to psoriasis: a meta-analysis of published serologic studies","volume":"113","author":"Mallon","year":"1999","journal-title":"J Invest Dermatol"},{"key":"R29-3-20210213","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1365-2133.2011.10688.x","article-title":"HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis","volume":"166","author":"Chiu","year":"2012","journal-title":"Br J Dermatol"},{"key":"R30-3-20210213","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.0022-202x.2001.01656.x","article-title":"HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features","volume":"118","author":"Gudj\u00f3nsson","year":"2002","journal-title":"J Invest Dermatol"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:23:27Z","timestamp":1620951807000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201609000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000233","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}